effective in treating CRS secondary to CAR-T cell therapy. The efficacy of tocilizumab in treating COVID-19 is unknown.

**Methods:** This was a retrospective study conducted at two hospitals in northern New Jersey. All patients treated with tocilizumab for confirmed or suspected COVID-19 between the dates of 3/10/20 and 4/9/20 at the study sites were included. The primary endpoint was clinical improvement on day 7 after treatment as assessed by respiratory status. Univariate analysis compared data between those who improved and those who did not.

**Results:** Forty five severe and critically ill patients treated with tocilizumab for COVID-19 were evaluated. Eleven (24%), 22 (49%) and 12 (27%) patients improved, and those who did not.

**Conclusion:** Tocilizumab administration was associated with a low rate of clinical improvement within 7 days in this cohort of severe and critically ill patients with COVID-19.

**Disclosures:** All Authors: No reported disclosures

### 555. Effectiveness of a Treatment Team on Adherence to Health System Guidelines for Hydroxychloroquine Use During Two Phases of the COVID-19 Epidemic

**J. Alex Viehman, MD; M. Hong Nguyen, MD; Will Garner, MD; Anna Apostolopoulos, MD; Devin H. Harris, MD; Aaron Lucas, MD; Vidya Singh, MD; Jack Klapper, PharmD, BCPS; Erin K. McCreary, PharmD, BCPS, BCIDP; Ricardo Arbulu, MD; Steven Ganchuk, PharmD; Anne Yang, MD; Amitha Avastara, MD; Rosalie Trifonate, MD; Rahul Bollam, MD; Richard H. Zou, MD; Kaveh Moghbeli, MD; Malik Darwish, MD; Amit Hemadi, MD; Erin Welshland, PharmD; Brian T. Campbell, MD; Maria S. Michalek, MD, MPH; Gladys Halder, PharmD; Jessica Dalf, PharmD; Elise Martin, MD; J. Ryan Barola, MD; 1University of Pittsburgh, Pittsburgh, Pennsylvania; 2University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; 3University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 4UPMC, Pittsburgh, Pennsylvania; 5Children's Hospital of Pittsburgh, Pittsburg, Pennsylvania; 6UPMC Mercy, Pittsburgh, Pennsylvania; 7UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania; 8Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; 9UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania; 10Institute for Pediatric Research, Pittsburgh, PA; 11University of Pittsburgh Medical Center, Infectious Disease Connect, Pittsburgh, Pennsylvania

**Session:** P-21. COVID-19 Treatment

**Background:** Our hospital system created system guidelines to standardize care across 24 hospitals for COVID-19 treatment during the pandemic. Guidelines changed over time. Hydroxychloroquine (HCQ) was unrestricted during phase 1, then restricted by pharmacy outside of a randomized clinical trial (RCT) during phase 2 (excepting those ineligible for RCTs).

**Methods:** This was a prospective study to assess system-wide adherence to COVID-19 treatment guidelines, and to evaluate patient outcomes.

**Results:** Of 261 patients, median age was 67 years (IQR 56–76); 49% (129/261) had a higher race-specific death rate (308 vs 197) per 1000 than white patients (p<0.001), mechanical ventilation (OR 4.9, 95%CI 2.0–11, p < 0.001), and severe adverse outcomes. A COVID-19 treatment team of physicians and pharmacists can effectively coordinate therapy across hospitals in the setting of rapidly changing guidelines.

**Disclosures:** J. Ryan Barola, MD, Infectious Disease Connect (Employee)Mayne Pharma (Advisor or Review Panel member)Merck (Research Grant or Support)

### 556. Evaluation of Hydroxychloroquine-based Combination Therapies for the Treatment of COVID-19

Andrea David, Berti, PharmD PhD; Pramodini Kale-Pradhan, PharmD; Christopher Guiano, PharmD MPH; Biana Aprilianno, BS; Christopher R. Miller, BA; Basma Alyashae, BS; Aishah Bhargava, MD; Leonard B. Johnson, MD; 1Wayne State University, Detroit, MI; 2Wayne State University/Ascension St. John Hospital, Detroit, MI; 3Wayne State University, Detroit, Michigan; 4Ascension St. John Hospital, Detroit, Michigan; 5Ascension St. John Hospital, Grosse Pointe Woods, MI

**Session:** P-21. COVID-19 Treatment

**Background:** During the early COVID-19 pandemic a large number of investigational agents were utilized due to lack of therapeutic options. We evaluate the utility of commonly-used investigational agents combined with hydroxychloroquine (HCQ).

**Methods:** This multicenter observational cohort study included patients admitted with COVID-19 between March - May 2020 in Detroit, Michigan who received at least 2 doses of HCQ. Our primary outcome was the change in sequential System Failure (SOFA) score from presentation to day 5 of HCQ therapy with a secondary outcome of in-hospital mortality. Data collected included demographics, Charlson Comorbidity index (CCI), daily SOFA score, laboratory data and COVID-directed therapies. Multiple linear regressions were performed to control for potential confounders between different therapies and change in SOFA score.

**Results:** Three hundred thirty-five patients receiving HCQ were included. Patients were 62 ± 14.8 years of age, male (54%) and African-American (82%) with a mean CCI of 1.7 ± 1.9. In our cohort, 32% were admitted to the intensive care unit and 35% expired. Therapies received by more than 20% of patients in addition to HCQ included azithromycin (80%), zinc (76%) and vitamin D (29%). In our unadjusted analysis, a significant improvement in SOFA score was observed with zinc (0.76) while no significant change was observed with azithromycin (-0.06) or vitamin D (0.05). However, there was no significant change in SOFA score after adjusting for confounders for azithromycin, zinc and vitamin D. No difference in mortality was observed between the groups.

**Conclusion:** Overall, no benefit in end-organ damage or mortality was observed with the addition of azithromycin, zinc or vitamin D to HCQ. Further studies are needed to confirm this observation.

**Disclosures:** All Authors: No reported disclosures

### 557. Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients

Jose Ramon Arribas, MD; Jose Ramon Arribas, MD; Arun J. Sanyal, MD; Alex Sorzano, MD; Bum Sik Chin, MD; Bum Sik Chin, MD; Shirin Kalimuddin, MD; Stefan Schreiber, MD; Emon Elboudwarej, PhD; Yuan Tian, PhD; Robert H. Hyland, MD; Devi SenGupta, MD; Anand Chokkalingam, PhD; Anu Ouniadi, MD; Diana M. Brainard, MD; Chistopher Liubert, MD; David Chien Boon Lye, MD; David Chien Boon Lye, MD; Judith A. Aberg, MD; 3Enrique Navas Elorza, MD; 4Jose Ramon Hyland, MD; 5Steven A. Zou, MD, PhD; 6Children Hospital of Pittsburgh of UPMC, Pittsburg, Pennsylvania; 7Hospital Universitario La Paz, Madrid, Madrid, Spain; 8VCU Health Medical Center, Richmond, Virginia; 9Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain; 10National Medical Center, Seoul, California; 11Singapore General Hospital, Singapore; 12Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania; 13National Heart and Lung Institute, London, United Kingdom

**Session:** P-21. COVID-19 Treatment

**Background:** Remdesivir (RDV) has been shown to shorten recovery time and was well tolerated in patients with severe COVID-19. Hydroxychloroquine (HQN) is an experimental treatment for COVID-19. Effects of coadministration of HQN with RDV have not been studied and are relevant given the long half-life (~22 days) of HQN. We report the impact of concomitant HQN and RDV use on clinical outcomes and safety in patients with moderate COVID-19.

**Methods:** We enrolled hospitalized patients with confirmed SAR-CoV-2 infection, oxygen saturation >94% on room air, and radiological evidence of pneumonia. Patients were randomized 1:1 to receive 5d or 10d of intravenous RDV once daily plus standard of care (SoC), or SoC only. We compared patients on concomitant HQN (HQN++) versus RDV (HQN–). Clinical recovery was evaluated using Cox proportional hazards. Covariate adjustment included age, sex, race, region, symptom duration, oxygen support status and obesity. Recovery and adverse events (AEs) were assessed through death, discharge, or d14.

**Results:** Of 584 patients, 199 (34%) received HQN (5d RDV: n=57 [30%]; 10d RDV, n=49 [25%]; SoC: n=93 [47%]). Through median follow-up of 13d (range 3–114d), HQN++ patients on 5d or 10d RDV had a lower recovery rate (adjusted HR [95% CI] 0.50 [0.25, 0.97], p=0.04) with longer median time to recovery (8 vs 6 days) compared to HQN–. HQN++ compared to HQN– showed a trend of reduced recovery rate (HR: 0.69 [0.45,1.04], p=0.080); such an effect was not observed in 10d RDV or SoC (Table 1). More HQN++ than HQN– patients had AEs in RDV (5/10d) or SoC arms evaluated separately, and all arms combined. This difference was significant for AEs and SAEs for all arms combined after covariate adjustment (Table 2).
## Conclusion:
In moderate COVID-19 patients, concomitant HQN may delay recovery on RDV and showed no impact on recovery with SoC alone. The AE profile of HQN® patients was worse than what observed for HQN® patients, regardless of RDV treatment.

### Disclosures:
Jose Ramon Arribas, MD, Alexa (Advisor or Review Panel member, Speaker's Bureau, Other Financial or Material Support, Personal fees); Gilead Sciences Inc. (Scientific Research Study Investigator, Advisor or Review Panel member, Speaker's Bureau, Other Financial or Material Support, Personal fees); Robert H. Hyland, MD (Advisor or Review Panel member, Speaker's Bureau, Other Financial or Material Support, Personal fees); Gilead Sciences Inc. (Employee, Shareholder); Robert H. Hyland, MD (Advisor or Review Panel member, Speaker's Bureau, Other Financial or Material Support, Personal fees); Zeneca (Consultant, Research Grant or Support); Viiv Healthcare (Advisor or Review Panel member, Speaker's Bureau, Other Financial or Material Support, Personal fees); Viiv Healthcare (Advisor or Review Panel member, Speaker's Bureau, Other Financial or Material Support, Personal fees); Jose Ramon Arribas, MD, NO DISCLOSURE DATA; Arun J. Sanyal, MD, AbbVie (Consultant); Akarna (Shareholder); Arvind (Consultant); Astra Zeneca (Consultant, Research Grant or Support); Boehringer (Consultant); Bristol-Myers Squibb (Research Grant or Support); Conatus (Consultant); Cumberland (Research Grant or Support); DirecT (Shareholder); Elsevier (Other Financial or Material Support, Royalties); Exhalenz (Shareholder); Fibrogen (Consultant); Genfit (Shareholder); Gilead Sciences Inc. (Consultant, Scientific Research Study Investigator, Research Grant or Support); Harmoshear (Shareholder); Indexx (Shareholder); Intercept (Research Grant or Support); Janssen (Consultant); Lilly (Consultant); Malinchkrd (Research Grant or Support); Merck (Research Grant or Support); Nimbus (Consultant); Nirmit Denko (Consultant); Novartis (Consultant); Pfizer (Consultant); Salix (Consultant); Sanyal Biotechnology (Employee, Shareholder, Other Financial or Material Support, President); Shire (Research Grant or Support); Takeda (Consultant); Tiziana (Shareholder); Tobira (Consultant); Uptodate (Other Financial or Material Support, Royalties); Zafgen (Consultant); Bum Sik Chin, MD, Gilead Sciences Inc. (Scientific Research Study Investigator); Emron Elboudwarej, PhD, Gilead Sciences Inc. (Employee, Shareholder); Yuan Tian, PhD, Gilead Sciences Inc. (Employee, Shareholder); Robert H. Hyland, MD, Gilead Sciences Inc. (Employee, Shareholder); Anand Chokkalingam, PhD, Gilead Sciences Inc. (Employee); Anu Oshinski, MD, Gilead Sciences Inc. (Employee); Christina Gallo, CHCP, Med Learning Group, New York, New York

## 559. Outcomes of Convalescent Plasma Transfusion for SARS-CoV2 Patients in the Intensive Care Unit
Rahayu Khalid, MD, PhD; Alvin G Thomas, MD, PhD; Daisy Zhu, MD; Iva Minga, MD; Nirmir Desai, MD; Leonard Kaplan, MD, PhD; University of Chicago (NorthShore), Evanston, Illinois; *NorthShore University Health System, Evanston, Illinois

### Session:
P-21. COVID-19 Treatment

#### Background:
SARS-CoV2 is a grave illness and few therapeutic agents have yielded benefit or reduced mortality. Administration of convalescent plasma (CP) in viral illnesses in the past, including SARS, before day 14, has been associated with a shorter hospital course. In the present study, we are interested in determining the benefit of administering CP to critically ill patients in the intensive care unit, and the impact on mortality and other clinical markers.

### Methods:
5 critically ill patients with confirmed SARS-CoV2 infection were observed in the uncontrolled case series study. Mechanically ventilated patients with severe ARDS (PaO2/FiO2 < 100) were eligible to receive CP transfusion. We reviewed daily vital signs, inflammatory markers, PaO2/FiO2 ratio and SOFA scores before and after CP transfusions. SARS-CoV2 PCR viral load testing was completed on day 0 of transfusion and repeated on day 3 and 6. Complications during the hospitalization and 30-day mortality were assessed.

### Results:
All 5 patients were mechanically ventilated at the time of transfusion and between day 7 to 31 of their illness. Following plasma transfusion, body temperature and inflammatory markers remained elevated in four patients (figure 1). SOFA score and PaO2/FiO2 ratios continued to worsen in three and four patients respectively (figure 2). SARS-CoV2 PCR remained positive in 4 patients. 4 of the 5 patients had died at the end of the follow up period. One patient was successfully extubated on day 29 (table 1) and discharged after a long hospital course.

### Trends of SOFA score and PaO2/FiO2 ratio

#### Figure 2. Trends of SOFA score and PaO2/FiO2 ratio

### Conclusion:
Advanced tools like virtual live learning platforms, mobile websites/apps, 3D animations & podcasts will prove to be an asset to the continuing education of HCPs treating patients with COVID-19. The outcomes are expected to demonstrate the extent to which HCPs have enhanced their ability to identify clinical predictors of disease severity of COVID-19 & apply current treatment guidelines, clinical trial data, & patient-specific factors to the management of patients with COVID-19. These results will be available in time to share via a poster at IDWeek 2020.

#### Disclosures:
All Authors: No reported disclosures

### 558. Innovative CME Tools in the Teaching of Evolving Strategies in the Management and Prevention of COVID-19
Brianza Hanson, BS; Lauren Welch, M.A.; Matthew Frese, MBA; Christina Gallo, CHCP, Med Learning Group, New York, New York

### Session:
P-21. COVID-19 Treatment

#### Background:
In 2020, Med Learning Group (MLG) launched an interactive, multi-faceted educational initiative focusing on COVID-19. The innovative education & tools developed for FRONTLINE are publicly available for the entire healthcare community to use. Learners range from a variety of specialties, including infectious disease specialists, pulmonary medicine specialists, emergency room practitioners, advanced practitioners, nurses, & other healthcare professionals to help support them in their effort to optimize care of patients with COVID-19.

MLG partnered with Health Resources & Services Administration, Project ECHO, Public Health Foundation & community, VA & academic centers to create a collaborative network with shared goals for education.

#### Methods:
This initiative seeks to reach over 25,000 learners with innovative educational programs & tools to enhance the learning experience, facilitate continuous learning & support the translation of education into practice, & encourage HCP-patient dialogue:
- COVID Community of Care Website/Application
- COVID Frontline Update Podcast Series
- Virtual/Live ECHO Series with 3D animations of pathophysiology
- Enduring ECHO Module with Case Discussions
- Quality Improvement Personalized Posters

#### Results:
By September 2020, we will have the results from pre/posttests, intra-activity Q&A, evaluations, & 60- to 90-day follow-on assessments. We will evaluate learners’ changes in knowledge & competence, & reported practice changes. In addition, MLG will have feedback collected via surveys & interviews on the various point-of-care tools. Based off previous MLG educational initiatives, it is expected that learners will find value in the various tools available in this programming.

#### Conclusion:
Advanced tools like virtual live learning platforms, mobile websites/apps, 3D animations & podcasts will prove to be an asset to the continuing education of HCPs treating patients with COVID-19. The outcomes are expected to demonstrate the extent to which HCPs have enhanced their ability to identify clinical predictors of disease severity of COVID-19 & apply current treatment guidelines, clinical trial data, & patient-specific factors to the management of patients with COVID-19. These results will be available in time to share via a poster at IDWeek 2020.

#### Disclosures:
All Authors: No reported disclosures

### Table 1. Time to Recovery by Concomitant HQN Use

| Treatment Group | HR [95% CI] | p-value |
|-----------------|-------------|---------|
| *5d/10d RDV combined (n=106) | 0.78 [0.59, 1.04] | 0.09 |
| 5d RDV (n=57) | 0.69 [0.45, 1.05] | 0.08 |
| 10d RDV (n=49) | 0.84 [0.56, 1.26] | 0.40 |
| SoC (n=93) | 1.08 [0.75, 1.56] | 0.68 |

All results adjusted for baseline oxygen support status, age, sex, race, obesity, symptom duration prior to treatment, region (Italy vs. other).

#### Table 2. Safety by Concomitant HQN Use for 5/10d RDV and SoC Arms Combined

| n (%) | HQN® (n=26) | HQN® (n=19) |
|-------|-------------|-------------|
| Any AE* | 181 (47%) | 112 (66%) |
| Any serious AE* | 16 (4%) | 17 (9%) |
| Any AE grade 3 | 41 (11%) | 24 (12%) |
| Death | 4 (1%) | 2 (1%) |

*Significant at p=0.05 after adjustment for baseline oxygen support status, age, sex, race, and treatment arm.

### Trends of SOFA socre and PaO2/FiO2

#### Figure 1. Fever curve and trends of inflammatory markers

#### Figure 2. Trends of SOFA score and PaO2/FiO2 ratio

---

S344 • OFID 2020:7 (Suppl 1) • Poster Abstracts